Hostname: page-component-76fb5796d-wq484 Total loading time: 0 Render date: 2024-04-25T13:27:02.502Z Has data issue: false hasContentIssue false

Cognitive Bias Modification to Prevent Depression in Mid to Late Life: the Cope Trial

Published online by Cambridge University Press:  15 April 2020

O. Almeida
Affiliation:
Psychiatry, The University of Western Australia, Perth, Australia
C. MacLeod
Affiliation:
Psychology, The University of Western Australia, Perth, Australia
B. Grafton
Affiliation:
Psychology, The University of Western Australia, Perth, Australia
A. Ford
Affiliation:
Psychiatry, The University of Western Australia, Perth, Australia
D. Glance
Affiliation:
Centre for Software Practive, The University of Western Australia, Perth, Australia
E. Holmes
Affiliation:
Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, United Kingdom

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Effective preventive strategies could reduce disability and the long term social and health complications associated with depression, but options are limited. Cognitive bias modification (CBM) is a novel, simple, and safe intervention that corrects the attentional and interpretive biases associated with depression.

Objectives

To determine if CBM decreases the one-year onset of major depression in adults at risk.

Methods

This randomised controlled trial will recruit adults with subsyndromal depression living in Australia (parallel design, 1:1 allocation ratio). The intervention will be delivered via the internet over 52 weeks. The primary outcome of interest is the onset of a major depression according to DSM-IV-TR criteria. Secondary outcomes of interest include change in the severity of depressive (Patient Health Questionnaire, PHQ-9) and changes in attention and interpretive biases. Outcomes will be collected 3, 6, 9 and 12 months after randomisation.

Results

Preliminary data on a subsample of 20 participants showed that the mean±SE PHQ-9 score of controls was 7.5±0.9 at study entry and 7.1±1.5 at week 6 (paired t-test=0.29, p=0.779), whereas the mean±SE score of active CBM participants was 7.4±1.0 and 4.4±1.1, respectively (paired t=6.00, p<0.001). The mean PHQ-9 difference between control and active CBM participants over 6 weeks was 2.6±1.5 points (t=1.79, p=0.090). One of 11 controls (9.1%) and 0/9 active CBM participants showed evidence of clinically significant depressive symptoms at week 6 (i.e., PHQ-9≥15).

Conclusions

By March 2015, 6-months preliminary data will be available on 165 participants.

Type
Article: 1309
Copyright
Copyright © European Psychiatric Association 2015
Submit a response

Comments

No Comments have been published for this article.